Most recently a significant study identified that the prognostic information provided by ‘IHC4’ (ER, PR, HER2 and Ki-67) was at least equivalent to Oncotype Dx (Cuzick et al, 2009) and highlights the relevance of these readily available routine pathology markers in the clinical management of breast cancer. Here, MKI67 is linked to breast carcinoma.